Influence of ABCB1 genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital

1 Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203-8. Search in Google Scholar

2 Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH. Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. J Support Oncol. 2005;3:149-54. Search in Google Scholar

3 Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. The Oncologist. 2007;12:1143-50. Search in Google Scholar

4 Lee HY, Kim HK, Lee KH, Kim BS, Song HS, Yang SH, et al. A randomized double-blind, double-dummy, multicenter trial of azasetron versus ondansetron to evaluate efficacy and safety in the prevention of delayed nausea and vomiting induced by chemotherapy. Cancer Res Treat. 2014;46:19-26. Search in Google Scholar

5 Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence based therapies. Am J Manag Care. 2017;23(14 Suppl):S259-65. Search in Google Scholar

6 Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22:469-77. Search in Google Scholar

7 Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer. 1994;74:1945-52. Search in Google Scholar

8 Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits. 2012;5:232. Search in Google Scholar

9 Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482-94. Search in Google Scholar

10 Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. The Oncologist. 2003;8:187-98. Search in Google Scholar

11 Sanchez LA, Holdsworth M, Bartel SB. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Pharmacoeconomics. 2000;18:533-56. Search in Google Scholar

12 Johnson NE, Nash DB, Carpenter CE, Sistek CJ. Ondansetron: costs and resource utilisation in a US teaching hospital setting. Pharmacoeconomics. 1993;3:471-81. Search in Google Scholar

13 Kris MG, Urba SG, Schwartzberg LS. Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion. Clin Adv Hematol Oncol. 2011;9:suppl 1-15. Search in Google Scholar

14 Farhat K, Ismail M, Ali S, Pasha AK. Resistance to ondansetron: Role of pharmacogenetics in post-operative nausea and vomiting. Egypt J Med Hum Genet. 2013;14:331-6. Search in Google Scholar

15 Tsuji D, Yokoi M, Suzuki K, Daimon T, Nakao M, Ayuhara H, et al. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J. 2016;1-6. Search in Google Scholar

16 Choi EM, Lee MG, Lee SH, Choi KW, Choi SH. Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Anaesthesia. 2010;65:996-1000. Search in Google Scholar

17 Babaoglu M, Bayar B, Aynacioglu A, Kerb R, Abali H, Celik I, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005;78:619-26. Search in Google Scholar

18 He H, Yin JY, Xu YJ, Li X, Zhang Y, Liu ZG, et al. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting. Clin Ther. 2014;36:1242-52. Search in Google Scholar

19 Umamaheswaran G, Krishna Kumar D, Kayathiri D, Rajan S, Shewade DG, Dkhar SA, et al. Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population. Mol Biol Rep. 2012;39:6343-51. Search in Google Scholar

20 Perwitasari DA, Wessels JAM, Straaten RJHMV, Pablo RFB, Mustofa M, Hakimi M, et al. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol. 2011;41:1168-76. Search in Google Scholar

21 Ghodke Y, Chopra A, Shintre P, Puranik A, Joshi K, Patwardhan B. Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians. Indian J Med Res. 2011;133:274-9. Search in Google Scholar

22 Farhat K, Iqbal J, Waheed A, Mansoor Q, Ismail M, Pasha AK. Association of anti-emetic efficacy of ondansetron with G2677T polymorphism in a drug transporter gene ABCB1 in Pakistani population. J Coll Physicians Surg Pak. 2015;25:486-90. Search in Google Scholar

23 Umamaheswaran G, Kumar DK, Adithan C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. Indian J Med Res. 2014;139:27-65. Search in Google Scholar